|
1
|
Yang K, Oak ASW, Slominski RM, Brożyna AA
and Slominski AT: Current molecular markers of melanoma and
treatment targets. Int J Mol Sci. 16:35352020. View Article : Google Scholar
|
|
2
|
Forsea AM: Melanoma epidemiology and early
detection in Europe: Diversity and disparities. Dermatol Pract
Concept. 10:e20200332020. View Article : Google Scholar
|
|
3
|
Elder DE, Massi D, Scolyer RA and Willemze
R: WHO Classification of Skin Tumours. 11. 4th edition. IARC
Publications; Geneva, CH: 2018
|
|
4
|
Shellenberger R, Nabhan M and Kakaraparthi
S: Melanoma screening: A plan for improving early detection. Ann
Med. 48:142–148. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mandalà M and Massi D: Tissue prognostic
biomarkers in primary cutaneous melanoma. Virchows Arch.
464:265–281. 2014. View Article : Google Scholar
|
|
6
|
Elder DE, Bastian BC, Cree IA, Massi D and
Scolyer RA: The 2018 World Health Organization classification of
cutaneous, mucosal, and uveal melanoma: Detailed analysis of 9
distinct subtypes defined by their evolutionary pathway. Arch
Pathol Lab Med. 144:500–522. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fong L and Small EJ: Anti-cytotoxic
T-lymphocyte antigen-4 antibody: The first in an emerging class of
immunomodulatory antibodies for cancer treatment. J Clin Oncol.
26:5275–5283. 2008. View Article : Google Scholar
|
|
8
|
Hodi FS, O'Day SJ, McDermott DF, Weber RW,
Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel
JC, et al: Improved survival with ipilimumab in patients with
metastatic melanoma. N Engl J Med. 363:711–723. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Topalian SL, Sznol M, McDermott DF, Kluger
HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB,
Powderly JD, et al: Survival, durable tumor remission, and
long-term safety in patients with advanced melanoma receiving
nivolumab. J Clin Oncol. 32:1020–1030. 2014. View Article : Google Scholar
|
|
10
|
Dummer R, Ascierto PA, Gogas HJ, Arance A,
Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer
R, et al: Encorafenib plus binimetinib versus vemurafenib or
encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): A
multicentre, open-label, randomised phase 3 trial. Lancet Oncol.
19:603–615. 2018. View Article : Google Scholar
|
|
11
|
Bastian BC: The molecular pathology of
melanoma: An integrated taxonomy of melanocytic neoplasia. Annu Rev
Pathol. 9:239–271. 2014. View Article : Google Scholar
|
|
12
|
Park CK and Kim SK: Clinicopathological
significance of intratumoral and peritumoral lymphocytes and
lymphocyte score based on the histologic subtypes of cutaneous
melanoma. Oncotarget. 8:14759–14769. 2017. View Article : Google Scholar
|
|
13
|
Maibach F, Sadozai H, Seyed Jafari SM,
Hunger RE and Schenk M: Tumor-infiltrating lymphocytes and their
prognostic value in cutaneous melanoma. Front Immunol. 11:21052020.
View Article : Google Scholar
|
|
14
|
Zablocka T, Nikolajeva A, Kreismane M,
Pjanova D and Isajevs S: Addressing the importance of melanoma
tumor-infiltrating lymphocytes in disease progression and
clinicopathological characteristics. Mol Clin Oncol. 15:2552021.
View Article : Google Scholar
|
|
15
|
Cancer Genome Atlas Network, . Genomic
classification of cutaneous melanoma. Cell. 161:1681–1696. 2015.
View Article : Google Scholar
|
|
16
|
Melis C, Rogiers A, Bechter O and van den
Oord JJ: Molecular genetic and immunotherapeutic targets in
metastatic melanoma. Virchows Arch. 471:281–293. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pracht M, Mogha A, Lespagnol A, Fautrel A,
Mouchet N, Le Gall F, Paumier V, Lefeuvre-Plesse C, Rioux-Leclerc
N, Mosser J, et al: Prognostic and predictive values of oncogenic
BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma. J Eur
Acad Dermatol Venereol. 29:1530–1538. 2015. View Article : Google Scholar
|
|
18
|
Ny L, Hernberg M, Nyakas M, Koivunen J,
Oddershede L, Yoon M, Wang X, Guyot P and Geisler J: BRAF
mutational status as a prognostic marker for survival in malignant
melanoma: A systematic review and meta-analysis. Acta Oncol.
59:833–844. 2020. View Article : Google Scholar
|
|
19
|
Rose EE, Egyházi S, Omholt K,
Månsson-Brahme E, Platz A, Hansson J and Lundeberg J: NRAS and BRAF
mutations in melanoma tumours in relation to clinical
characteristics: A study based on mutation screening by
pyrosequencing. Melanoma Res. 6:471–478. 2006. View Article : Google Scholar
|
|
20
|
Eigentler T, Assi Z, Hassel JC,
Heinzerling L, Starz H, Berneburg M, Bauer J and Garbe C: Which
melanoma patient carries a BRAF-mutation? A comparison of
predictive models. Oncotarget. 7:36130–36137. 2016. View Article : Google Scholar
|
|
21
|
Davies H, Bignell GR, Cox C, Stephens P,
Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W,
et al: Mutations of the BRAF gene in human cancer. Nature.
417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Long GV, Menzies AM, Nagrial AM, Haydu LE,
Hamilton AL, Mann GJ, Hughes TM, Thompson JF, Scolyer RA and
Kefford RF: Prognostic and clinicopathologic associations of
oncogenic BRAF in metastatic melanoma. J Clin Oncol. 29:1239–1246.
2011. View Article : Google Scholar
|
|
23
|
Ito T, Tanaka Y, Murata M, Kaku-Ito Y,
Furue K and Furue M: BRAF heterogeneity in melanoma. Curr Treat
Options Oncol. 22:202021. View Article : Google Scholar
|
|
24
|
Colebatch AJ, Ferguson P, Newell F,
Kazakoff SH, Witkowski T, Dobrovic A, Johansson PA, Saw RPM,
Stretch JR, McArthur GA, et al: Molecular genomic profiling of
melanocytic nevi. J Invest Dermatol. 139:1762–1768. 2019.
View Article : Google Scholar
|
|
25
|
Chiappetta C, Proietti I, Soccodato V,
Puggioni C, Zaralli R, Pacini L, Porta N, Skroza N, Petrozza V,
Potenza C, et al: BRAF and NRAS mutations are heterogeneous and not
mutually exclusive in nodular melanoma. Appl Immunohistochem Mol
Morphol. 23:172–177. 2015. View Article : Google Scholar
|
|
26
|
Thomas NE, Edmiston SN, Alexander A,
Groben PA, Parrish E, Kricker A, Armstrong BK, Anton-Culver H,
Gruber SB, From L, et al: Association between NRAS and BRAF
mutational status and melanoma-specific survival among patients
with higher-risk primary melanoma. JAMA Oncol. 1:359–368. 2015.
View Article : Google Scholar
|
|
27
|
Cheng L, Lopez-Beltran A, Massari F,
MacLennan GT and Montironi R: Molecular testing for BRAF mutations
to inform melanoma treatment decisions: A move toward precision
medicine. Mod Pathol. 31:24–38. 2018. View Article : Google Scholar
|
|
28
|
Tas F and Erturk K: Clinical and
prognostic significance of BRAF V600E mutation in non-metastatic
cutaneous melanoma patients. Neoplasma. 66:631–636. 2019.
View Article : Google Scholar
|
|
29
|
Bezić J, Kuret S, Vrbičić B, Smolić J,
Borić I, Škifić I, Ledina D and Božić J: Clinicopathological
characteristics of BRAF V600E mutated melanomas in the dalmatian
region of croatia. Acta Dermatovenerol Croat. 27:225–230. 2019.
|
|
30
|
Spathis A, Katoulis AC, Damaskou V, Liakou
AI, Kottaridi C, Leventakou D, Sgouros D, Mamantopoulos A,
Rigopoulos D, Karakitsos P and Panayiotides IG: BRAF mutation
status in primary, recurrent, and metastatic malignant melanoma and
its relation to histopathological parameters. Dermatol Pract
Concept. 9:54–62. 2019.
|
|
31
|
Kim SY, Kim SN, Hahn HJ, Lee YW, Choe YB
and Ahn KJ: Metaanalysis of BRAF mutations and clinicopathologic
characteristics in primary melanoma. J Am Acad Dermatol.
72:1036–1046.e2. 2015. View Article : Google Scholar
|
|
32
|
Estrozi B, Machado J, Rodriguez R and
Bacchi CE: Clinicopathologic findings and BRAF mutation in
cutaneous melanoma in young adults. Appl Immunohistochem Mol
Morphol. 22:57–64. 2014. View Article : Google Scholar
|
|
33
|
Aksenenko MB, Kirichenko AK and Ruksha TG:
Russian study of morphological prognostic factors characterization
in BRAF-mutant cutaneous melanoma. Pathol Res Pract. 211:521–527.
2015. View Article : Google Scholar
|
|
34
|
Platz A, Egyhazi S, Ringborg U and Hansson
J: Human cutaneous melanoma; a review of NRAS and BRAF mutation
frequencies in relation to histogenetic subclass and body site. Mol
Oncol. 1:395–405. 2008. View Article : Google Scholar
|
|
35
|
Weiss SA, Han SW, Lui L, Tchack J, Shapiro
R, Berman R, Zhong J, Krogsgaard M, Osman I and Darvishian F:
Immunologic heterogeneity of tumor-infiltrating lymphocyte
composition in primary melanoma. Hum Pathol. 57:116–125. 2016.
View Article : Google Scholar
|
|
36
|
Leslie C, Bowyer SE, White A,
Grieu-Iacopetta F, Trevenen M, Iacopetta B, Amanuel B and Millward
M: FOXP3+ T regulatory lymphocytes in primary melanoma are
associated with BRAF mutation but not with response to BRAF
inhibitor. Pathology. 47:557–563. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jakob JA, Bassett RL Jr, Ng CS, Curry JL,
Joseph RW, Alvarado GC, Rohlfs ML, Richard J, Gershenwald JE, Kim
KB, et al: NRAS mutation status is an independent prognostic factor
in metastatic melanoma. Cancer. 118:4014–4023. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lee JH, Choi JW and Kim YS: Frequencies of
BRAF and NRAS mutations are different in histological types and
sites of origin of cutaneous melanoma: A meta-analysis. Br J
Dermatol. 164:776–784. 2011. View Article : Google Scholar
|
|
39
|
Ugurel S, Thirumaran RK, Bloethner S, Gast
A, Sucker A, Mueller-Berghaus J, Rittgen W, Hemminki K, Becker JC,
Kumar R and Schadendorf D: B-RAF and N-RAS mutations are preserved
during short time in vitro propagation and differentially impact
prognosis. PLoS One. 2:e2362007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Devitt B, Liu W, Salemi R, Wolfe R, Kelly
J, Tzen CY, Dobrovic A and McArthur G: Clinical outcome and
pathological features associated with NRAS mutation in cutaneous
melanoma. Pigment Cell Melanoma Res. 24:666–672. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Heppt MV, Siepmann T, Engel J,
Schubert-Fritschle G, Eckel R, Mirlach L, Kirchner T, Jung A,
Gesierich A, Ruzicka T, et al: Prognostic significance of BRAF and
NRAS mutations in melanoma: A German study from routine care. BMC
Cancer. 17:5362017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ellerhorst JA, Greene VR, Ekmekcioglu S,
Warneke CL, Johnson MM, Cooke CP, Wang LE, Prieto VG, Gershenwald
JE, Wei Q and Grimm EA: Clinical correlates of NRAS and BRAF
mutations in primary human melanoma. Clin Cancer Res. 17:229–235.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Schlaak M, Bajah A, Podewski T, Kreuzberg
N, von Bartenwerffer W, Wardelmann E, Merkelbach-Bruse S, Büttner
R, Mauch C and Kurschat P: Assessment of clinical parameters
associated with mutational status in metastatic malignant melanoma:
A single-centre investigation of 141 patients. Br J Dermatol.
168:708–716. 2013. View Article : Google Scholar
|
|
44
|
Bucheit AD, Syklawer E, Jakob JA, Bassett
RL Jr, Curry JL, Gershenwald JE, Kim KB, Hwu P, Lazar AJ and Davies
MA: Clinical characteristics and outcomes with specific BRAF and
NRAS mutations in patients with metastatic melanoma. Cancer.
119:3821–3829. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Grimaldi AM, Simeone E, Festino L, Vanella
V, Strudel M and Ascierto PA: MEK inhibitors in the treatment of
metastatic melanoma and solid tumors. Am J Clin Dermatol.
18:745–754. 2017. View Article : Google Scholar
|
